Psilocybin
New Study: Challenging Psychedelic Trips Lead to Positive Mental Health
The article New Study: Challenging Psychedelic Trips Lead to Positive Mental Health was originally published on Microdose.
A new study suggests that challenging…
The article New Study: Challenging Psychedelic Trips Lead to Positive Mental Health was originally published on Microdose.
A new study suggests that challenging and mystical psychedelic experiences may be connected to improved mental health outcomes.
The research was published in the Journal of Affective Disorders and reviewed survey data from almost 1,000 respondents regarding their personal experiences with psychedelics.
As reported in this article by the Ohio State News, the data suggested a connection between the intensity of mystical or insightful psychedelic experiences – and reported improvements in mental health like anxiety and depression symptoms.
The analysis also showed that challenging experiences during psychedelic trips can potentially lead to beneficial mental health results after the difficult period has passed. These patterns were observed across all psychedelic substances, including 5-MeO-DMT, Ayahuasca, LSD, mescaline, psilocybin, and peyote
See the study here.
For more like this, check out New Study Shows SSRIs Ineffective Compared to Psychedelics and Can LSD Make You Smarter? New Study Shows Positive Results
ayahuasca peyote mescaline psilocybin lsd dmt psychedelic depression anxiety research psychedelics
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
MindBio Landmark Sleep Research Published in Prestigious Nature Portfolio Journal Translational Psychiatry
Tryp Therapeutics merger with Exopharm approved by shareholders
Adastra reports record sales in 2023, but remains in the red
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
Tryp Therapeutics, Exopharm merger approved by shareholders
The First Wave of Blotter Acid Inspired Trippy Psychedelic Art
-
Psychedelics1 week agoCybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
-
Law & Regulation1 week agoGoing concern warnings cloud Xtacy Therapeutics’ shrunk losses
-
Psilocybin1 week agoAre Shrooms Legal in Oregon: Full Guide
-
Psychedelics1 week agoOptimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
-
Psychedelics1 week ago
Atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
-
Psychedelics1 week agoPsyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
-
Law & Regulation1 week agoClearmind signs agreement with Hebrew University for psychedelic compound rights
-
Psychedelics7 days agoRevive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product